IL263786B - Crystalline forms of 4-(5-(7,4-dimethylbenzofuran-2-yl)-4,2,1-oxadiazol-3-yl)benzoic acid and processes for their preparation - Google Patents
Crystalline forms of 4-(5-(7,4-dimethylbenzofuran-2-yl)-4,2,1-oxadiazol-3-yl)benzoic acid and processes for their preparationInfo
- Publication number
- IL263786B IL263786B IL263786A IL26378618A IL263786B IL 263786 B IL263786 B IL 263786B IL 263786 A IL263786 A IL 263786A IL 26378618 A IL26378618 A IL 26378618A IL 263786 B IL263786 B IL 263786B
- Authority
- IL
- Israel
- Prior art keywords
- dimethylbenzofuran
- oxadiazol
- processes
- preparation
- benzoic acid
- Prior art date
Links
- AVCXUODHLRZJJP-UHFFFAOYSA-N 4-[5-(4,7-dimethyl-1-benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound CC1=CC=C(C2=C1C=C(O2)C1=NC(=NO1)C1=CC=C(C(=O)O)C=C1)C AVCXUODHLRZJJP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- AIDS & HIV (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1610867.2A GB201610867D0 (en) | 2016-06-22 | 2016-06-22 | Crystalline forms of a therapeutic compound and processes for their preparation |
| PCT/EP2017/064802 WO2017220446A1 (en) | 2016-06-22 | 2017-06-16 | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL263786A IL263786A (en) | 2019-01-31 |
| IL263786B true IL263786B (en) | 2022-05-01 |
Family
ID=56895172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL263786A IL263786B (en) | 2016-06-22 | 2018-12-18 | Crystalline forms of 4-(5-(7,4-dimethylbenzofuran-2-yl)-4,2,1-oxadiazol-3-yl)benzoic acid and processes for their preparation |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10870644B2 (enExample) |
| EP (1) | EP3475274A1 (enExample) |
| JP (1) | JP7102354B2 (enExample) |
| CN (1) | CN109415356B (enExample) |
| AU (1) | AU2017279865B2 (enExample) |
| CA (1) | CA3025858C (enExample) |
| GB (1) | GB201610867D0 (enExample) |
| IL (1) | IL263786B (enExample) |
| MX (1) | MX387013B (enExample) |
| WO (1) | WO2017220446A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| GB201907647D0 (en) * | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| CN111238897B (zh) * | 2020-02-18 | 2023-03-28 | 上海市皮肤病医院 | 生物标本的处理方法与处理剂 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259795T3 (es) | 1995-06-07 | 2006-10-16 | Nippon Shinyaku Company, Limited | Derivados de pirrol y composicion medicinal. |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| KR100485642B1 (ko) * | 1996-03-18 | 2005-09-30 | 에자이 가부시키가이샤 | 축합고리함유카르복실산유도체 |
| JPH10158192A (ja) | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
| GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
| US6355669B1 (en) | 1997-10-22 | 2002-03-12 | Eisai Co., Ltd. | Retinoic acid agonists as preventive and therapeutic agents for nephritis |
| US7041685B2 (en) | 2001-06-08 | 2006-05-09 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| WO2003062230A1 (en) | 2002-01-21 | 2003-07-31 | Eisai Co., Ltd. | Conbinatorial library of heterocycle compounds |
| WO2004014881A2 (en) | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| EP4101846B1 (en) | 2003-04-11 | 2023-08-02 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| JP2008515992A (ja) | 2004-10-13 | 2008-05-15 | ピーティーシー セラピューティクス，インコーポレーテッド | 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用 |
| JP2009501721A (ja) | 2005-07-12 | 2009-01-22 | アカディア ファーマシューティカルズ インコーポレイテッド | レチノイン酸受容体における活性を伴う化合物 |
| WO2008057930A2 (en) | 2006-11-02 | 2008-05-15 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with retinoic acid receptor agonists |
| AU2009253046A1 (en) | 2008-05-30 | 2009-12-03 | Foster Wheeler Energia Oy | Method of and system for generating power by oxyfuel combustion |
| EP2314569A1 (en) * | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| WO2011072281A1 (en) | 2009-12-11 | 2011-06-16 | Ptc Therapeutics, Inc. | Methods for treating methylmalonic acidemia |
| CN107207488B (zh) * | 2014-12-17 | 2020-11-17 | 伦敦皇家学院 | 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物 |
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
-
2016
- 2016-06-22 GB GBGB1610867.2A patent/GB201610867D0/en not_active Ceased
-
2017
- 2017-06-16 JP JP2018566470A patent/JP7102354B2/ja active Active
- 2017-06-16 WO PCT/EP2017/064802 patent/WO2017220446A1/en not_active Ceased
- 2017-06-16 CA CA3025858A patent/CA3025858C/en active Active
- 2017-06-16 US US16/311,318 patent/US10870644B2/en active Active
- 2017-06-16 MX MX2018016250A patent/MX387013B/es unknown
- 2017-06-16 CN CN201780038472.8A patent/CN109415356B/zh active Active
- 2017-06-16 AU AU2017279865A patent/AU2017279865B2/en active Active
- 2017-06-16 EP EP17733396.0A patent/EP3475274A1/en active Pending
-
2018
- 2018-12-18 IL IL263786A patent/IL263786B/en unknown
-
2020
- 2020-12-02 US US17/109,758 patent/US11584741B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10870644B2 (en) | 2020-12-22 |
| AU2017279865B2 (en) | 2020-11-26 |
| MX387013B (es) | 2025-03-19 |
| CA3025858C (en) | 2023-09-26 |
| CA3025858A1 (en) | 2017-12-28 |
| GB201610867D0 (en) | 2016-08-03 |
| EP3475274A1 (en) | 2019-05-01 |
| IL263786A (en) | 2019-01-31 |
| AU2017279865A1 (en) | 2019-01-03 |
| CN109415356A (zh) | 2019-03-01 |
| JP7102354B2 (ja) | 2022-07-19 |
| WO2017220446A1 (en) | 2017-12-28 |
| CN109415356B (zh) | 2022-03-08 |
| MX2018016250A (es) | 2019-08-29 |
| JP2019522650A (ja) | 2019-08-15 |
| US20210230151A1 (en) | 2021-07-29 |
| US11584741B2 (en) | 2023-02-21 |
| US20190345147A1 (en) | 2019-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256237B (en) | Solid forms of (z) - 4 - (5 - ((3 - benzyl - 4 - oxo - 2 - thioxothiazolidine - 5 - ylidin) methyl) furan - 2 - yl) benzoic acid | |
| IL247833A0 (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| SI3097098T1 (sl) | Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina | |
| LT3267984T (lt) | 1,2,4-oksadiazolo ir tiadiazolo junginiai kaip imunomoduliatoriai | |
| HUE039869T2 (hu) | N-Azaspirocikloalkán helyettesített N-heteroaril vegyületek és készítmények az SHP2 aktivitás gátlására | |
| HUE056583T2 (hu) | 6-Karboxi-2-(3,5-diklórfenil)-benzoxazol kristályos szilárd formái | |
| ZA201606386B (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| IL247653B (en) | Pharmaceutical compositions and benzoic acid salts of 4,2,1-oxadiazole | |
| SG11201707384YA (en) | Crystal of 3,5-disubstituted benzene alkynyl compound | |
| DK3185867T3 (da) | Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni | |
| IL273896A (en) | Crystal forms of 3-disubstituted 1, 2, 4-oxadiazole | |
| DK3390407T3 (da) | Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser | |
| HUE045851T2 (hu) | Eljárás 2-(2,5-dimetil-1H-pirrol-1-il)-1,3-propándiol és helyettesített származékainak elõállítására | |
| EP3262039A4 (en) | Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof | |
| IL253239A0 (en) | Method for preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3h-imidazo[5,4[b-pyridin-2-yl)pyridin-2-amine | |
| SI3298008T1 (sl) | Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol | |
| IL249248A0 (en) | Non-aqueous crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-2,1-benzaisoxazole | |
| EP3339306A4 (en) | Novel crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and preparation method thereof | |
| PT2943488T (pt) | Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1 | |
| PL3212644T3 (pl) | Pochodne 2-(1,2,4-triazol-3-ilosulfanylo)-n-1,3,4-tiadiazol-2 -iloacetamidu, które są przydatne w leczeniu cukrzycy | |
| GB2559718B (en) | Novel crystalline form of tribenuron-methyl, process for preparation and use thereof | |
| SG11201701674RA (en) | Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same | |
| SI3143019T1 (sl) | Kristalna oblika 6-((4R)-4-metil-1,2-dioksido-1,2,6-tiadiazinan-2-IL)isokvinolin-1- karbonitrila | |
| IL263299A (en) | Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent | |
| TH1601000138A (th) | เกลือชนิดใหม่ของ 3-[(3-{[4-(4-มอร์โฟลินิลเมทธิล)-1h-ไพร์รอล-2-อิล]เมทธิลลีน}-2-ออกโซ-2,3-ไดไฮโดร-1h-อินดอล-5-อิล)เมทธิล]-1,3-ไธอะโซลิดีน-2,4-ไดโอน การเตรียมของมันและสูตรผสมที่มีมันประกอบอยู่ |